Co-targeting the MAPK pathway using a BRAF and CDK 4/6 inhibitor combination therapy is a novel approach to potentially overcome intrinsic or de novo BRAF inhibitor resistance in BRAF-mutant melanoma and may be investigated in future clinical trials. This evidence concerns the gene BRAF and melanoma.